HIV drug maraviroc effective for drug-resistant patients

October 02, 2008

As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.

Results of the two Phase 3 multicenter MOTIVATE (Maraviroc Plus Optimized Therapy in Viremic Antiretroviral Treatment Experienced Patients) studies led by NewYork-Presbyterian Hospital/Weill Cornell Medical Center's Dr. Roy Gulick and published in the October 2 issue of the New England Journal of Medicine (NEJM) find that the drug, taken with an optimized standard HIV drug regimen, resulted in significantly greater suppression of the virus at 48 weeks, with concurrent increases in immune system T-cell counts, when compared with placebo. Rates of side effects were not different between the maraviroc and placebo groups.

Preliminary results of these studies led to FDA approval of maraviroc in August 2007.

Because it is from a new class of HIV medications known as HIV entry inhibitors, people living with HIV generally will not have resistance to maraviroc because they have not been exposed to any drugs from the class previously. Unlike earlier HIV drugs that target the virus, maraviroc acts on the human T-cell, binding to it in such a way that prevents HIV from binding and subsequently infecting the T-cell.

"It is now possible to expect that a majority of treatment-experienced patients who experience failure on their current HIV drugs will regain control of their HIV infection with maraviroc combined with other newer antiretroviral drugs. This is an important step forward," says study principal investigator Dr. Roy Gulick, who is professor of medicine and director of the Cornell HIV Clinical Trials Unit of the Division of International Medicine and Infectious Diseases at Weill Cornell Medical College, and a practicing physician at NewYork-Presbyterian Hospital in New York City. "Suppressing virus levels and increasing immune system T-cells with HIV treatment regimens helps HIV-infected people live longer, healthier lives."

The double-blind study followed 1,049 of patients with advanced HIV and resistance to three antiretroviral drug classes. Patients were randomized to receive maraviroc once-daily, twice-daily or placebo. Safety and efficacy were assessed at 48 weeks. The MOTIVATE studies comprised two identical arms: MOTIVATE1 was conducted in Canada and the U.S., while MOTIVATE2 was conducted in Australia, Europe and the U.S.

More patients receiving maraviroc once- or twice-daily versus placebo achieved HIV-1 RNA <50 copies/mL (43-46% vs. 17%). CD4 counts increased more with maraviroc once- or twice-daily versus placebo (+116-124 vs. +61 cells/µL). Frequencies of side effects and toxicities were similar across groups.

A subgroup analyses of the MOTIVATE trials is also published in the October 2 edition of NEJM. "Findings from the subgroup analyses show that maraviroc plus standard antiretroviral regimen provides consistent clinical benefit over placebo plus optimized background therapy for all subgroups analyzed," said Dr. Gerd Fätkenheuer, lead-author of the subgroup analyses and professor of medicine, Universitätsklinik Köln, Köln, Germany. "Results highlight that maraviroc provides a valuable additional treatment option for a wide spectrum of treatment-experienced patients with R5 HIV-virus infection."

Currently there are 25 FDA-approved HIV medications in six classes, including HIV entry inhibitors like maraviroc, used in various combinations to treat HIV and AIDS. In cases of drug resistance, medicines lose their ability to fight HIV. Some drugs become less effective while others can become completely ineffective. As viruses reproduce, they make copy after copy of themselves, growing in number with each replication. Sometimes, small errors in one virus will be passed on to the next viral copy. Over time, viruses that contain these small errors become larger in number. These small changes in the virus's genetic make-up are called mutations. It's these mutations that cause resistance to HIV medications. Often, resistance to one medication means resistance to an entire class of medications.

New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

---

---

	INITIATING HIV THERAPY: Timing is critical, controversial A concise synopsis of recent research data and current guidelines on when to initiate antiretroviral ... and side effects. (Postgraduate Medicine) by JTE Multimedia Currently available antiretroviral drug regimens are able to suppress HIV replication and allow CD4 recovery in the vast majority of patients with HIV infection. The challenge is to match each patient to the regimen that is most likely to durably suppress HIV replication enough to prevent resistance selection without causing treatment-limiting toxicities. It is also critical, but difficult, to know when to begin treatment relative to CD4 cell count and plasma viral load. In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options. Original Publication Date: February 2004
	Tables: Antiretroviral Agents (Postgraduate Medicine) by JTE Multimedia Abstract: National Institutes of Health. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV–infected adults and adolescents. HIV/AIDS Treatment Information Service. January 29, 2008. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed October 9, 2008. Original Publication Date: November 2008
	DESIGNING SALVAGE ANTIRETROVIRAL REGIMENS: Some basic guidelines and use of resistance testing (Postgraduate Medicine1) by JTE Multimedia In the field of HIV medicine, the term "salvage regimen" refers to one that is constructed for a patient in whom multiple previous regimens have been unsuccessful, for a wide variety of reasons. Although such regimens may have unproved efficacy, they are based on some solid scientific data or principles. In this article, the authors discuss the current state of genotyping and phenotyping used for resistance testing, the challenges involved in interpreting the data they provide, and factors to keep in mind when considering a switch to a different treatment regimen. Hardy WD, Hitt RS. Designing salvage antiretroviral regimens: some basic guidelines and use of resistance testing. Original Publication Date: April 2000
	Mortal Combat: AIDS Denialism and the Struggle for Antiretrovirals in South Africa by Nicoli Nattrass (Author)
	A Decade of HAART: The Development and Global Impact of Highly Active Antiretroviral Therapy by Josï¿1/2 M Zuniga (Editor), Alan Whiteside (Editor), Amin Ghaziani (Editor), John G Bartlett (Editor) Highly active antiretroviral therapy (HAART) is a therapeutic intervention developed by clinicians and researchers in order to fight the HIV pandemic. It has contributed to a significant reduction in AIDS-related mortality and allowed many previously bed-ridden patients to live healthier, more productive lives. Until the advent of HAART in 1996, a diagnosis of HIV infection was considered a death sentence. A decade later, the disease has been transformed into a serious, yet potentially manageable, medical condition for thousands of people living with HIV/AIDS in the developed world - almost overnight creating a generation of "HIV Survivors" - and forged a global movement to ensure that its Lazarus-like benefit reaches millions more in the developing world. This book reviews the...
	Anti-retroviral: Webster's Timeline History, 1987 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Anti-retroviral," including when used in literature (e.g. all authors that might have Anti-retroviral in their name). As such, this book represents the largest compilation of timeline events associated with Anti-retroviral when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	Antiretroviral: Webster's Timeline History, 1896 - 2006 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Antiretroviral," including when used in literature (e.g. all authors that might have Antiretroviral in their name). As such, this book represents the largest compilation of timeline events associated with Antiretroviral when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	Antiretroviral: Webster's Timeline History, 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Antiretroviral," including when used in literature (e.g. all authors that might have Antiretroviral in their name). As such, this book represents the largest compilation of timeline events associated with Antiretroviral when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	A Practical Guide to HIV Drug Resistance and Its Implications for Antiretroviral Treatment Strategies (HIV Clinical Management Series) by Douglas Richman and Schlomo Staszewski (Author)
	Antidepressants and Labor Market Outcomes of Persons Living with HIV: An Analysis of Users of Highly-Active Antiretroviral Therapy in the United States: 1996-2004 by Omar Galarraga (Author), David S. Salkever (Author) The work examines the effect of antidepressants on the employment of HIV-positive persons receiving highly active antiretroviral therapy (HAART). It uses U.S. panel data (1996-2004) from the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS). Regression models of employment control for: demographic characteristics, clinical indicators, physical and mental health summary measures and local area characteristics. Instrumental variables help identify antidepressant use. The results show that antidepressant use has a positive effect on the employment probability of women living with HIV. Among women receiving HAART, and controlling for individual and local area labor market characteristics, use of antidepressants is associated with a higher probability of being...